Mizuho Securities Maintains Their Hold Rating on Abeona Therapeutics (ABEO)


In a report released today, Difei Yang from Mizuho Securities maintained a Hold rating on Abeona Therapeutics (ABEO), with a price target of $4.00. The company’s shares closed last Monday at $2.94.

According to TipRanks.com, Yang has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.8% and a 38.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Xeris Pharmaceuticals, and Revance Therapeutics.

Currently, the analyst consensus on Abeona Therapeutics is a Moderate Buy with an average price target of $9.50.

See today’s analyst top recommended stocks >>

Based on Abeona Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $17.37 million. In comparison, last year the company had a GAAP net loss of $16.42 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts